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AbstrAct
Accurate detection of altered anaplastic lymphoma kinase (ALK) expression is 
critical for the selection of lung cancer patients eligible for ALK-targeted therapies. 
To overcome intrinsic limitations and discrepancies of currently available companion 
diagnostics for ALK, we developed a simple, affordable and objective PCR-based 
predictive model for the quantitative measurement of any ALK fusion as well as wild-
type ALK upregulation. This method, optimized for low-quantity/-quality RNA from 
FFPE samples, combines cDNA pre-amplification with ad hoc generated calibration 
curves. All the models we derived yielded concordant predictions when applied to a 
cohort of 51 lung tumors, and correctly identified all 17 ALK FISH-positive and 33 of 
the 34 ALK FISH-negative samples. The one discrepant case was confirmed as positive 
by IHC, thus raising the accuracy of our test to 100%. Importantly, our method was 
accurate when using low amounts of input RNA (10 ng), also in FFPE samples with 
limited tumor cellularity (5–10%) and in FFPE cytology specimens. Thus, our test is 
an easily implementable diagnostic tool for the rapid, efficacious and cost-effective 
screening of ALK status in patients with lung cancer.
IntroductIon
The anaplastic lymphoma kinase (ALK) is a 
transmembrane receptor tyrosine kinase involved in the 
pathogenesis of different types of human cancers, including 
anaplastic large-cell lymphoma, neuroblastoma and non-
small cell lung cancer (NSCLC) [1–4]. In NSCLC, ALK is 
rearranged in approximately 3–7% of all patients [4–7], and 
in 20–30% of the subset of lung adenocarcinoma patients 
who are young and non-/light smokers [6–8].
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ALK (2p23) rearranges primarily with the 
echinoderm microtubule-associated protein-like 4 (EML4, 
2p21) in NSCLC leading to the expression of the EML4-
ALK fusion oncogene [4, 5]. Several EML4-ALK fusion 
variants have been identified in NSCLC [9], as well as 
other less-frequent ALK translocations involving different 
fusion partners [5, 10–14]. While ALK expression is 
negligible in the normal lung adult tissue [4], these 
genetic rearrangements lead to the constitutive expression 
of chimeric proteins comprised of the kinase domain-
containing C-terminus of ALK fused to the N-terminus of 
the translocation partner, which directs ligand-independent 
dimerization and activation of ALK [4, 5]. In addition 
to ALK rearrangements, ALK gene amplification has 
also been detected in NSCLC [7, 15, 16], which might 
represent an additional mechanism of ALK activation, 
although its clinical significance is yet to be determined 
[15].
The identification of ALK translocations in NSCLC 
has opened the door to the use of targeted therapies for 
the treatment of these lung cancers. Crizotinib is a well-
tolerated first generation ALK inhibitor [17, 18] that has 
been shown to be superior to standard chemotherapy both 
as a first- and second-line treatment [19, 20], while second 
generation ALK inhibitors, such as alectinib and ceritinib, 
are effective not only in crizotinib-naïve patients, but also 
in those patients with acquired resistance to crizotinib 
[21–24]. The availability of these targeted therapies 
has prompted the development of diagnostic assays and 
algorithms that can accurately identify ALK-positive 
lung cancers patients. Although several methodologies 
have been developed, they display discrepant results 
[25–31] and often have limited applicability to formalin-
fixed, paraffin-embedded (FFPE) tissue samples, the 
major source material for diagnostic testing [25]. Thus, a 
consensus on the optimal technique and testing algorithm 
has not yet been reached in the clinical setting [25, 32].
Two leading FDA approved ALK diagnostic tests are 
the break-apart fluorescence in situ hybridization (FISH) 
assay (Vysis ALK Break Apart FISH Probe Kit), and the 
automated immunohistochemistry (IHC) assay (Ventana 
ALK (D5F3) CDx Assay). These two tests show a good 
level of correlation [33] and in a recent international 
interpretation study they demonstrated an overall 
sensitivity, specificity and accuracy of 90%, 95% and 
93%, respectively [34]. However, the use of alternative 
approaches, i.e. reverse transcription-polymerase chain 
reaction (RT-PCR) and/or next-generation sequencing 
(NGS), has been recommended to resolve discordant or 
borderline cases [35, 36]. 
Real-time PCR represents a more quantitative 
and sensitive technology with reduced inter-observer 
variability, when compared with FISH and IHC. Yet, some 
limitations prevent its full implementation in the clinical 
setting. Firstly, established multiplex RT-PCR assays for 
the detection of all the different ALK rearrangements 
require continuous optimization, given the increasing 
numbers of fusion variants and partners identified [37, 38]. 
Secondly, more recent reverse transcription quantitative 
real-time PCR (RT-qPCR) assays based on the unbalanced 
expression of the 5′ and 3′ portions of the ALK transcript 
[39–41], which occurs when ALK is rearranged, require 
significant amounts of RNA (50–100 ng per PCR reaction) 
from FFPE tissues  [40, 41]. Alternative technologies that 
could be applied to the detection of ALK rearrangements, 
i.e., NanoString (NanoString Technologies, Inc., Seattle, 
WA) and RNA massive parallel sequencing require, in 
addition to elevated amounts of total RNA, the availability 
of proprietary and cutting-edge platforms in pathology 
laboratories [42, 43]. To circumvent these problems, 
we describe herein, a simple quantitative PCR-based 
ALK predictive model fully optimized to work with 
low-quantity and low-quality RNA from FFPE samples. 
The test, by targeting both the 5′ and 3′ portions of 
ALK mRNA, detects any ALK translocation as well as 
overexpression of full-length ALK.
results
optimization of the rt-qPcr assay for the 
detection of ALK alterations in FFPe nsclc 
samples
The breakpoint of ALK occurs, by and large, before 
its intracellular kinase domain (exon 20). When ALK is 
translocated, its C-terminal portion (exons 20–29) is 
consistently expressed in the chimeric transcript while 
its N-terminal part (exons 1–19) is lost. Therefore, 
measuring the unbalanced expression of the C- and 
N-terminal portions of the ALK transcript in a given 
sample is a reliable method to indirectly identify ALK 
rearrangements, regardless of fusion partner and variant 
type. Based on this rationale, we selected two different RT-
qPCR assays, one targeting exons 27–28 in the 3´ region 
and the other targeting exons 9–10 in the 5´ region of ALK 
(Figure 1A). In this way, our test is able to detect both 
known and unknown ALK fusions as well as wild-type 
ALK upregulation. 
To optimize the RT-qPCR analysis of ALK 
expression from limited amounts of degraded RNA 
from FFPE tissues, we selected probes targeting short 
regions (< 90 bp in size) of the transcript to increase the 
probability of detection. We also implemented a multiplex 
pre-amplification method designed for the dual purpose 
of stretching precious sample material into more qPCR 
reactions and of improving the signal-to-noise ratio for the 
detection of low/moderate-abundance transcripts. 
To test the specificity of the two ALK assays, we 
employed RNA from FFPE samples of: i) Kelly cells 
expressing readily detectable levels of full-length ALK 
transcript, containing both the 3′ and 5′ portions of ALK 
mRNA [2]; ii) NCI-H2228 cells expressing an EML4-
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ALK translocation, thus positive only for the 3′ portion 
of the ALK mRNA [5]; iii) A549 cells expressing barely 
detectable levels of the normal ALK transcript, used as a 
negative control [5].  
As expected, the 3′ assay detected ALK expression 
levels only in Kelly and NCI-H2228 cells, while the 5′ 
ALK assay was positive only in Kelly cells (Figure 1B). 
When the assays were tested on fresh-frozen (FF) samples 
of the above cell lines and compared with the results 
from the FFPE samples, similar expression patterns were 
detected (Supplementary Table S1). Importantly, the 
relative expression patterns of both the 3′ and 5′ portions 
of the ALK transcript were comparable in the three FFPE 
cell lines with and without pre-amplification, indicating 
an equal and efficient pre-amplification of cDNA for 
all the selected targets (Figure 1B and Supplementary 
Table S1). Indeed, the mean pre-amplification uniformity 
values (ΔΔCq) relative to the two ALK assays, measured 
in Kelly cells were largely within the ± 1.5 value that is 
generally accepted for uniform pre-amplification reactions 
(5′ ALK ΔΔCq: – 0.09 ± 0.20; 3′ ALK ΔΔCq: 0.01 ± 0.14; 
Supplementary Table S2). In addition, pre-amplification 
resulted in mean Cq improvements of around 8 cycles: 
e.g., 7.85 ± 0.13 cycles (range: 7.64−7.99) in Kelly cells 
(see Supplementary Table S3 for a complete analysis of 
the 3 cell lines). 
Figure 1: optimization of the rt-qPcr assays for the detection of the ALK transcript. (A) The position of the two different 
ALK PCR assays relative to the domain structure of the ALK protein is shown. SigP, signal peptide; MAM (meprin, A-5 protein, and 
receptor protein-tyrosine phosphatase mu) domains; LDLa (Low-density lipoprotein receptor domain class A) domain; G-rich domain 
(glycine-rich); TM (Transmembrane) domain; KD (kinase domain). The ALK breakpoint that leads to fusion proteins in different cancers 
is indicated (zigzag line). (b) Relative expression levels of the 5′ and 3′ portions of the ALK transcript calculated using the formula 
2−ΔCq (where ΔCq = CqALK – average CqREF) in FFPE Kelly, NCI-H2228, and A549 cells with (+ PreAMP) or without (– PreAMP) pre-
amplification are reported. Error bars indicate 95% confidence intervals (three independent experiments, n = 3).
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development of an accurate model to predict 
AlK expression
To predict accurately the expression levels of the 5′ 
and 3′ portions of ALK in NSCLC samples, we used the 
calibration curves generated with RNA from Kelly and 
NCI-H2228 cells (see details in Materials and Methods). 
The curves were used to develop different predictive 
models, based on an inverse prediction approach [44], for 
the quantitative assessment of the 3′ and 5′ or only the 3′ 
portion of the ALK transcript. 
Initially, we compared the calibration curves 
prepared with Kelly cells in the presence or absence of 
pre-amplification. The two linear fits and associated 
residual sum of squares (RSS) of the data points relative 
to the 3′ and 5′ ALK portions, obtained with these two 
calibration curves, were comparable (3′ ALK –/+PreAMP, 
R2 = 0.99/0.99, RSS = 1.17/1.23; 5′ ALK –/+PreAMP, 
R2 = 0.98/0.98, RSS = 1.97/1.46, Supplementary 
Figure S1A–B). Moreover, Cq improvements of ~7.57 ± 
0.40 cycles for the 5′ and ~7.38 ± 0.35 cycles for the 3′ 
portion of ALK across all the data points of the dilution 
range were retained (Supplementary Table S4). To control 
for the balanced expression of the 3′ and 5′ portions of 
ALK, we calculated the difference between the ΔCq of the 
3′ and of the 5′ portion of ALK (ΔΔCq
3′–5′ALK
 = ΔCq
3′ALK
-
ΔCq
5′ALK
), relative to the endogenous controls, for each 
data point of the two calibration curves, in the presence 
and absence of pre-amplification. These ΔΔCq values are 
expected to remain stable across the dilution range in the 
case of balanced 3′/5′ ALK expressions. ΔΔCq values were 
more stable in the pre-amplified (range = – 0.36 – 0.03; 
median = – 0.10; Q1 = – 0.15; Q3 = – 0.03) vs. not pre-
amplified (range = – 0.91 − 0.38; median = – 0.30; Q1 
= – 0.41; Q3 = – 0.22) calibration curve (Supplementary 
Figure S1C). Based on these results, pre-amplification 
was included in the generation of the calibration curve for 
NCI-H2228 cells, which behaved similarly to Kelly cells 
(Supplementary Figure S1D).
Next, we derived different fitting models using 
the Kelly and NCI-H2228 calibration curves, either 
by covering the entire 1–100% dilution range or by 
restricting the analysis to the 1–50% dilution range, 
where a better sensitivity of the assay is desirable. 
For the 3′ portion of ALK, we used both the Kelly and 
NCI-H2228 calibration curves, separately and pooled, 
as they are representative of both ALK full-length 
expression and translocation. For the 5′ portion of ALK 
we used only the curves obtained with Kelly cells. 
Overall, the different linear fits (6 for the 3′ and 2 for the 
5′ ALK) were similar (R2 range = 0.98–0.99; Figure 2). 
Parameters relative to the various derived algorithms 
(Supplementary Table S5) were then used to convert ALK 
transcript expression measured in NSCLC samples by 
RT-qPCR into percentages of 3′ and/or 5′ ALK transcript 
positivity, as described in the following section.
Validation of the AlK predictive model in a 
cohort of nsclc patients
To define the threshold value for ALK positivity 
(abnormal ALK expression) in NSCLC samples, we 
applied the different predictive models to a set of 20 lung 
FFPE non-pathological tissue samples. Based on the low 
basal levels of 3′ ALK and barely detectable levels of 
5′ ALK, measured in non-pathological lung tissues, the 
threshold value of ALK positivity was set at 10% and 3% 
for the 3′ and 5′ portions, respectively (Supplementary 
Tables S6A–S6B). 
Next, we applied the derived models to predict ALK 
status in a cohort of 51 NSCLC FFPE samples, previously 
characterized by FISH for ALK translocation, composed of 
17 FISH positive and 34 FISH negative samples (Table 1). 
Of note, we obtained RT-qPCR data of adequate quality 
for all 51 FFPE NSCLC samples, as determined using the 
interquartile rule for outliers (see Materials and Methods 
and Supplementary Table S7). All models gave 100% 
concordant binary predictions (ALK translocated or not 
translocated) for all the 51 FFPE NSCLC samples, with 
minor differences in the percentage of 3′ and/or 5′ ALK 
positivity (Supplementary Table S8). Moreover, models 
generated in the 1–50% dilution range exhibited narrower 
95% confidence intervals for all the predicted percentages 
of 3′ and 5′ ALK positivity (including those > 50%), 
compared with the models derived from the 1–100% 
dilution range (ΔCq data were simulated ranging from 
0 to 15, every 0.01 units, as shown in Figure 3A–3C). 
No significant differences were observed between the 
predictions obtained with the Kelly and the NCI-H2228 
models in the 1–50% dilution range (Figure 3B). Thus, 
we used the algorithms generated with the Kelly model, 
which allows the concomitant detection of both the 3′ and 
5′ portions of ALK, to predict ALK status in the NSCLC 
cohort (Figure 3D). 
Our model identified all the 17 ALK FISH-positive 
samples as translocated. Indeed, all these samples 
showed an elevated percentage of 3′ positivity compared 
with the percentage of 5′ positivity, thereby confirming 
the presence of an unbalanced expression of the two 
ALK regions as a consequence of a translocation event 
(Table 2). Among the 34 FISH-negative cases, 33 resulted 
not translocated by our method, while one sample was 
clearly detected as translocated (Case ID #19, 3′ ALK 
positivity of 58.6%; 95% CI: 47–73.5), despite its scarce 
tumor cellularity (5%, Table 2). This sample, with a 
marginal percentage of FISH positive nuclei (10%; 
Table 2), was ALK-positive by IHC analysis using the 
automated IHC Ventana assay, in agreement with our PCR 
assay. Thus, these data indicate that the discrepant FISH 
result was a false negative and, importantly, that our test 
reliably identifies ALK translocations in specimens with 
limited tumor cellularity, as low as 5–10% (Case ID #13, 
#15 and #19, Table 2).
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table 1: clinico-pathological characteristics of the nsclc cohort composed of 51 surgical and 
7 cytology specimens analyzed for ALK expression
case
Id
Age
(yrs)
sex Histology eGFr/KrAs
Mutation
tumor site
(Primary/
Metastasis)
specimen
Analyzed
FIsH
AlK
1 54 F ADK NEG/NEG Metastasis Pleura POS
2 65 F ADK NEG/NEG Primary Lung POS
3 48 F ADK NEG/NEG Metastasis Pleura POS
4 47 M ADK ND/ND Metastasis Lymph node POS
5 81 F ADK ND/NEG Primary Lung POS
6 66 M ADK NEG/NEG Primary Lung POS
7 38 F ADK NEG/NEG Primary Lung POS
8 58 M ADK NEG/NEG Metastasis Lymph node POS
9 38 F ADK NEG/NEG Metastasis Lymph node POS
10 49 F ADK NEG/NEG Metastasis Lymph node POS
11 47 F ADK NEG/NEG Metastasis Pleura POS
12 52 F ADK NEG/NEG Primary Lung POS
13 61 M ADK NEG/NEG Metastasis Pleura POS
14 51 F ADK NEG/NEG Metastasis Lymph node POS
15 66 M ADK NEG/NEG Metastasis Pleura POS
16 36 F ADK NEG/NEG Primary Lung POS
17 44 F ADK ND/ND Primary Lung POS
18 61 M ADK POS/NEG Metastasis Pleura NEG
19 54 F ADK NEG/NEG Primary Lung NEG
20 70 M ADSK + NET NEG/NEG Primary Lung NEG
21 68 M ADK POS/NEG Primary Lung NEG
22 61 M ADK NEG/POS Primary Lung NEG
23 63 M ADK NEG/NEG Primary Lung NEG
24 56 F PC NEG/POS Primary Lung NEG
25 65 F ADK NEG/POS Primary Lung NEG
26 58 M ADK NEG/NEG Primary Lung NEG
27 63 M ADK NEG/POS Primary Lung NEG
28 80 M ADK NEG/POS Primary Lung NEG
29 58 F ADSK NEG/NEG Primary Lung NEG
30 49 M ADK POS/NEG Metastasis Pleura NEG
31 68 M ADK NEG/ND Primary Lung NEG
32 71 M ADK NEG/ND Primary Lung NEG
33 65 M ADK NEG/NEG Primary Lung NEG
34 50 F ADK NEG/ND Primary Lung NEG
35 53 M ADK NEG/POS Primary Lung NEG
36 53 F ADK NEG/ND Primary Lung NEG
37 59 M ADK NEG/NEG Primary Lung NEG
38 78 M ADSK NEG/ND Primary Lung NEG
39 68 F ADK NEG/ND Primary Lung NEG
40 68 M ADK NEG/NEG Primary Lung NEG
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41 60 M ADK NEG/POS Primary Lung NEG
42 59 M ADK NEG/ND Primary Lung NEG
43 61 F ADK NEG/ND Primary Lung NEG
44 71 M ADK NEG/POS Metastasis Pleura NEG
45 62 F ADK NEG/POS Primary Lung NEG
46 66 M ADK NEG/POS Metastasis Pleura NEG
47 46 F SCC POS/NEG Metastasis Parietal Pleura NEG
48 63 M ADK POS/NEG Metastasis Lymph node NEG
49 73 F ADK NEG/NEG Metastasis Lymph node NEG
50 72 M ADK NEG/POS Metastasis Pleura NEG
51 50 M ADK NEG/POS Primary Lung NEG
52 55 F ADK NEG/NEG Metastasis Lymph node/Cytology NEG
53 82 M ADK NEG/NA Metastasis Lymph node/Cytology NEG
54 68 M ADK NEG/POS Metastasis Lymph node/Cytology NEG
55 64 M ADK NEG/NEG Metastasis Lymph node/Cytology NEG
56 63 M ADK NEG/NA Metastasis Lymph node/Cytology NEG
57 75 M ADK NEG/POS Metastasis Lymph node/Cytology POS
58 56 F ADK NEG/NEG Metastasis Lymph node/Cytology POS
Case IDs #1–51 refer to surgical specimens and Case IDs #52–58 refer to cytology specimens obtained by EBUS. Age at 
surgery is indicated (yrs); F, female; M, male; ADK, adenocarcinoma; ADSK, adenosquamous cell carcinoma; ADSK + 
NET, adenosquamous cell carcinoma + neuroendocrine; SCC, squamous; PC, pleomorphic carcinoma of the lung; EGFR, 
epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; POS, positive; NEG, negative; ND, 
not determined or missing data; ALK, anaplastic lymphoma kinase; FISH, fluorescent in situ hybridization.
Among the 33 tumors identified as not translocated 
by our PCR assay, two exhibited a level of 3′ positivity 
significantly above the 10% cut-off (Case ID #20, 13.5%; 
Case ID #25, 15.5%, Table 2). Both these samples, 
however, showed percentages of 5′ positivity comparable 
to the 3′ portion (Table 2), suggesting that they did not 
harbor an ALK translocation, but rather expressed low/
moderate levels of normal ALK transcripts. Together, 
these results showed that our diagnostic model reached 
a sensitivity, specificity and accuracy of 100%, 97% and 
98%, respectively, compared with FISH.
To evaluate whether our predictive model was 
accurate when using low quantities of input RNA, 
representative FFPE NSCLC samples (21 in total), 
covering a wide range of ALK positivity, were processed 
using 25 and 10 ng of total RNA instead of 100 ng. The 
predictions relative to the three different RNA quantities 
(100, 25 and 10 ng) were 100% concordant, indicating that 
our model reliably detects ALK status in FFPE NSCLC 
samples also when the input RNA is scarce (Table 3).
Finally, we analyzed 7 cytological FFPE samples (5 
ALK FISH-negative and 2 ALK FISH-positive), obtained 
with the minimally invasive endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) 
procedure, using 10 ng input RNA (Table 1). Our assay 
correctly identified all the 5 FISH-negative cases and 
one of the two FISH-positive cases (Case ID #58, with 
38% of FISH positive nuclei; Table 4). Notably, the one 
discordant case (Case ID #57, with a borderline 20% of 
FISH-positive nuclei) was confirmed to be negative by 
subsequent IHC analysis. 
In summary, our diagnostic model reached a 
sensitivity, specificity and accuracy of 95%, 97% and 97%, 
respectively, compared with FISH on a total of 58 FFPE 
NSCLC samples (51 surgical and 7 cytology specimens) 
(Figure 4). Notably, the two discrepant cases (one surgical 
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Figure 2: development of various AlK models using external calibration curves. (A–F) Correlation plots of the expression 
values (grey dots) of the 3′ portion of ALK relative to the 1–100% and the 1–50% dilution range in Kelly (A and B), NCI-H2228 (C and D), 
and pooled Kelly + NCI-H2228 (E and F) calibration curves. (G–H) Correlation plots of the expression values (grey dots) of the 5′ portion 
of ALK relative to the 1–100% (G) or the 1–50% (H) dilution range in the Kelly calibration curves. For all curves, linear fit (solid blue line) 
and 95% prediction limits (dashed blue line) are reported. Relative expression values of the 3′ (ΔCq−3′) or the 5′ (ΔCq−5′) portion of ALK 
normalized to internal controls (ΔCq = CqALK – average CqREF) by known percentage (log-transformed, base 10, Log %) of total RNA of 
ALK positive cells in the different calibration curves are indicated. R2, coefficient of determination; RSS, residual sum of squares relative 
to the 1–100% (RSS1–100%), the 1–50% (RSS1–50%) and the 10–20% (RSS10–20%) dilution series, are shown.
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table 2: Accuracy of the Pcr-based predictive model in the assessment of AlK status in the 51 
nsclc cohort
case
Id
FIsH rt-qPcr Model - Kelly (1–50%)  
100 ng rnA
tumor 
cell 
content 
(%)
tumor site
(Primary/
Metastasis)
specimen 
Analyzed
AlK
score
Positive 
nuclei (%)
ALK
status
3′ ALK 
Positivity (%)
5′ ALK 
Positivity (%)
1 POS 90 T 82.6 (66.0–100) 0 30 Metastasis Pleura
2 POS 64 T 100 (100–100) 0 60 Primary Lung
3 POS 87 T 100 (100–100) 0 60 Metastasis Pleura
4 POS 61 T 100 (81.1–100) 0 80 Metastasis Lymph node
5 POS 55 T 100 (100–100) 0 80 Primary Lung
6 POS 61 T 100 (98.4–100) 0 70 Primary Lung
7 POS 70 T 100 (100–100) 0 60 Primary Lung
8 POS 50 T 100 (100–100) 0 60 Metastasis Lymph node
9 POS 50 T 100 (100–100) 0 60 Metastasis Lymph node
10 POS 53 T 100 (100–100) 0 70 Metastasis Lymph node
11 POS 31 T 75.4 (60.3–95.0) 0 20 Metastasis Pleura
12 POS 35 T 100 (100–100) 0 30 Primary Lung
13 POS 23 T 97.7 (77.8–100) 0 10 Metastasis Pleura
14 POS 24 T 91.1 (72.6–100) 0 40 Metastasis Lymph node
15 POS 32 T 55.8 (44.8–69.9) 8.7 (6.8–11.0) 5 Metastasis Pleura
16 POS 24 T 100 (100–100) 0 50 Primary Lung
17 POS 25 T 100 (100–100) 0 60 Primary Lung
18 NEG 8 NT 0 0 70 Metastasis Pleura
19 NEG 10 T 58.6 (47.0–73.5) 0 5 Primary Lung
20 NEG 3 NT 13.5 (10.9–16.6) 11.0 (8.6–14.0) 80 Primary Lung
21 NEG 0 NT 4.6 (3.7–5.7) 1.2 (0.9–1.5) 70 Primary Lung
22 NEG 8 NT 6.2 (5.0–7.7) 0 60 Primary Lung
23 NEG 2 NT 3.8 (3.1–4.8) 0 80 Primary Lung
24 NEG 5 NT 0.8 (0.6–1.0) 0 60 Primary Lung
25 NEG 11 NT 15.5 (12.5–19.2) 24.4 (19.2–31.3) 50 Primary Lung
26 NEG 0 NT 5.5 (4.4–6.8) 0 30 Primary Lung
27 NEG 5 NT 4.4 (3.6–5.5) 4.9 (3.8–6.3) 30 Primary Lung
28 NEG 0 NT 3.3 (2.7–4.1) 0 60 Primary Lung
29 NEG 1 NT 1.8 (1.4–2.2) 0 80 Primary Lung
30 NEG 4 NT 0 0 70 Metastasis Pleura
31 NEG 3 NT 2.0 (1.6–2.5) 0 80 Primary Lung
32 NEG 3 NT 5.4 (4.4–6.7) 2.0 (1.5–2.5) 80 Primary Lung
33 NEG 0 NT 0 0 80 Primary Lung
34 NEG 4 NT 8.8 (7.1–10.9) 13.1 (10.3–16.7) 90 Primary Lung
35 NEG 0 NT 0 0 60 Primary Lung
36 NEG 0 NT 0 0 60 Primary Lung
37 NEG 5 NT 0 0 80 Primary Lung
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and one cytological) were confirmed as positive by IHC, 
thus raising the accuracy of our test to 100%.
dIscussIon 
The discovery of effective ALK-targeted therapies 
for the treatment of NSCLC demands that we improve our 
ability to identify patients eligible for treatment. The FDA-
approved break-apart FISH assay represented the gold 
standard for the detection of ALK rearrangements during 
the crizotinib trials. However, given the difficulty in signal 
interpretation [45], the FISH assay yields erroneous results 
[18, 21, 23, 46, 47]. The recently approved Ventana ALK 
IHC (D5F3) CDx assay is a viable alternative to FISH. 
Although this IHC assay provides a simple digital reading 
of ALK status to limit inter-observer variability, a qualified 
pathologist is needed to grade the result and proprietary 
stainer and kits are required. Therefore, more quantitative, 
objective, and open source methodologies could find 
widespread application in clinical laboratories and help to 
resolve discrepant cases and/or equivocal results. 
Quantitative PCR is a reliable and extremely 
sensitive technique for the measurement of clinical 
biomarkers. Optimal PCR-based ALK assays in clinical 
practice should be i) versatile (able to detect any ALK 
alteration), ii) accurate (especially when using low 
quantity, poor quality and low tumor cellularity FFPE 
biological samples), iii) user-friendly (implementable in 
routine clinical labs), and iv) cost-effective (particularly 
relevant for the screening of large, low-incidence 
populations). Our simple RT-qPCR-based predictive 
model fulfills these requirements. The combination of a 
simple inverse prediction model with an optimized RT-
qPCR protocol showed that our ALK test was superior 
to the break-apart FISH assay in a cohort of 58 FFPE 
NSCLC cases, composed of 51 surgical and 7 cytology 
38 NEG 5 NT 0 0 70 Primary Lung
39 NEG 2 NT 4.3 (3.4–5.3) 2.4 (1.9–3.1) 70 Primary Lung
40 NEG 2 NT 2.9 (2.3–3.6) 0 60 Primary Lung
41 NEG 4 NT 1.7 (1.4–2.1) 0 60 Primary Lung
42 NEG 13 NT 0 0 40 Primary Lung
43 NEG 6 NT 0 0 80 Primary Lung
44 NEG 13 NT 0.9 (0.7–1.1) 0 80 Metastasis Pleura
45 NEG 1 NT 0 0 40 Primary Lung
46 NEG 3 NT 3.6 (2.9–4.4) 6.5 (5.1–8.3) 5 Metastasis Pleura
47 NEG 4 NT 0.9 (0.7–1.1) 0 70 Metastasis Parietal 
Pleura
48 NEG 2 NT 6.0 (4.8–7.4) 0 40 Metastasis Lymph node
49 NEG 1 NT 1.8 (1.4–2.2) 0 40 Metastasis Lymph node
50 NEG 4 NT 0 0 20 Metastasis Pleura
51 NEG 1 NT 0 0 60 Primary Lung
Kelly – – NT 100 (100–100) 100 (100–100) – – –
NCI-H2228 – – T 71.8 (57.4–90.3) 0 – – –
A549 – – NT 0 0 – – –
Binary ALK status by FISH analysis is indicated as positive (POS, ≥ 15% of positive nuclei) or negative (NEG, < 15% 
of positive nuclei). Percentage (%) of FISH positive nuclei with separated green and red signals or single red signals 
(translocation and deletion of the ALK 5′ portion, respectively) are reported when available. Binary ALK status determined 
by the PCR-based model analysis is indicated as Translocated (T) or Not Translocated (NT) based on the predicted percentage 
of 3′ and 5′ ALK positivity measured in each FFPE NSCLC sample (positivity cut-off value for the 3′ and 5′ ALK portions 
were 10% and 3%, respectively). Predicted percentages of 3′ and 5′ ALK positive RNA present in FFPE NSCLC samples 
are reported along with the 95% confidence intervals in brackets. These values were calculated from the data obtained in the 
RT-qPCR analysis by the ALK inverse prediction models obtained from the Kelly calibration curves for the 3′ and 5′ portions 
of ALK. The model was derived considering the 1–50% dilution series of the external calibration curves. ALK transcript 
expression was measured using the PCR protocol optimized for FFPE samples starting from 100 ng of input RNA. The 
percentage (%) of tumor cell content is also indicated for each sample. ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in-situ hybridization; RT-qPCR, quantitative reverse transcription-polymerase chain reaction.
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specimens. Overall, our diagnostic model reached a 
sensitivity, specificity and accuracy of 95%, 97% and 
97%, respectively, compared with FISH (Tables 2 and 4, 
Figure 4), and further validation on a larger cohort is now 
merited. Notably, the accuracy of our test rose to 100% 
when the FISH false-negative surgical sample and the 
FISH false-positive cytology sample were reclassified as 
ALK-positive and ALK-negative, respectively, according 
to IHC (Figure 4). Our predictive test also provided 
high percentages of 3′ ALK positivity in samples with 
borderline percentages of FISH-positive nuclei (range 
= 10–35%), demonstrating superior sensitivity (Table 2 
and Table 3). Additionally, our assay was accurate when 
using as little as 10 ng of input RNA, also in samples 
with low tumor cellularity (5–10%, Tables 2 and 3) and in 
cytological specimens (Table 4), which is frequently the 
only clinical material available in patients with advanced 
lung cancer. Notably, in a couple of cases (Case ID #20 
and #25, Table 2), our test detected overexpression of full-
length ALK, in the absence of ALK translocation (Table 2). 
Whether this higher expression identifies a small fraction 
of lung cancers sensitive to ALK inhibitors remains to be 
established. In addition, by targeting exons 27–28 in the 3′ 
portion of ALK, our assay is able to detect also the recently 
identified ALK isoforms (though rare in lung cancer), 
encompassing exons 20–29 [48]. 
Our test offers several advantages over published 
[39–43] assays assessing the unbalanced expression of 
the 3′ and 5′ portion of ALK transcript: i) it requires at 
least 5–10 times less input RNA; ii) it does not require 
expensive and proprietary technologies or specialist 
expertise (unlike NanoString and/or NGS platforms), and 
Figure 3: Comparison of the confidence bands in the different models and validation of the Kelly 1–50% ALK 
predictive model using FFPe nsclc samples. (A–b) Confidence bands at 95% for predicted percentages of 3′ ALK positivity 
relative to the calibration curves in the 1–100% (A) or the 1–50% (B) range with NCI-H2228 (blue lines), Kelly (red lines) and Kelly + 
NCI-H2228 (black lines) for the ALK 3′ portion. (c) Confidence bands at 95% for predicted percentages of 5′ ALK positivity specific to the 
Kelly calibration curves in the 1–100% (green line) or the 1–50% (orange line) range. ΔCq data were simulated ranging from 0 to 15, every 
0.01 units. Estimates were obtained through inverse prediction models considering the indicated calibration curves and dilution series. (d) 
Predicted percentage (and 95% confidence bars) of 3′ (blue dots) and 5′ (red dots) ALK portions for the 17 FISH-positive and 34 FISH-
negative NSCLC samples. Blue and red lines indicate the threshold for the 3′ (10%) and 5′ (3%) ALK positivity, respectively.
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Figure 4: study design for the development of the rt-qPcr-based prediction model and the validation on 58 FFPe 
nsclc tissue specimens. Schematic representation of the analysis of ALK status in the NSCLC cohort. The cohort was composed 
of 51 surgical and 7 cytology FFPE NSCLC specimens (see Table 1). Binary ALK status by FISH analysis is indicated as positive (POS, 
≥ 15% of positive nuclei) or negative (NEG, < 15% of positive nuclei). Binary ALK status determined by the PCR-based model analysis is 
indicated as Translocated (T) or Not Translocated (NT) based on the predicted percentage of 3′ and 5′ ALK positivity (cut-off values for 3′ 
and 5′ ALK portions were 10% and 3%, respectively). Binary ALK status by IHC is indicated as positive (POS) or negative (NEG) based on 
the presence or lack of a strong granular cytoplasmic staining in tumor cells, respectively.
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table 3: Accuracy of ALK status prediction in a selected subset of 21 nsclc samples using 100, 25 
and 10 ng of input rnA
case
Id
FIsH rt–qPcr Model - Kelly (1–50%) tumor
cell
content
(%)
100 ng rnA 25 ng rnA 10 ng rnA
AlK
score
Positive
nuclei 
(%)
ALK
status
3′ ALK
Positivity 
(%)
5′ ALK
Positivity 
(%)
ALK
status
3′ ALK
Positivity 
(%)
5′ ALK
Positivity 
(%)
ALK
status
3′ ALK
Positivity 
(%)
5′ ALK
Positivity 
(%)
5 POS 55 T 100 (100–100) 0 T 100 (100–100) 0 T 100 (100–100) 0 80
6 POS 61 T 100 (98.4–100) 0 T 100 (82.8–100) 0 T 96.4 (76.8–100) 0 70
7 POS 70 T 100 (100–100) 0 T 100 (100–100) 0 T 100 (100–100) 0 60
8 POS 50 T 100 (100–100) 0 T 100 (100–100) 0 T 100 (100–100) 0 60
9 POS 50 T 100 (100–100) 0 T 100 (100–100) 0 T 100 (100–100) 0 60
11 POS 31 T 75.4 (60.3–95.0) 0 T 83.8 (66.9–100) 0 T 100 (100–100) 0 20
13 POS 23 T 97.7 (77.8–100) 0 T 79.7 (63.7–100) 0 T 85.5 (68.3–100) 0 10
16 POS 24 T 100 (100–100) 0 T 100 (100–100) 0 T 100 (100–100) 0 50
19 NEG 10 T 58.6 (47.0–73.5) 0 T 48.5 (39.0.–60.7) 0 T 63.7 (51.1–80.0) 0 5
20 NEG 3 NT 13.5 (10.9–16.6) 11.0
(8.6–14.0)
NT 10.3 (8.3–12.7) 11.6 
(9.1–14.8)
NT 8.9 (7.2–11.0) 9.0  
(7.0–11.4)
80
21 NEG 0 NT 4.6 (3.7–5.7) 1.2 
(0.9–1.5)
NT 5.1 (4.1–6.3) 1.3 
(1.0–1.6)
NT 5.4 (4.4–6.7) 3.0 
(2.3–3.9)
70
22 NEG 8 NT 6.2 (5.0–7.7) 0 NT 5.2 (4.2–6.5) 0 NT 4.3 (3.5–5.4) 0 60
23 NEG 2 NT 3.8 (3.1–4.8) 0 NT 3.5 (2.8–4.3) 0 NT 4.7 (3.8–5.9) 0 80
26 NEG 0 NT 5.5 (4.4–6.8) 0 NT 4.4 (3.6–5.5) 0 NT 7.6 (6.2–9.4) 0 30
38 NEG 5 NT 0 0 NT 0 0 NT 0 0 70
39 NEG 2 NT 4.3 (3.4–5.3) 2.4 
(1.9–3.1)
NT 6.4 (5.1–7.9) 4.4 
(3.4–5.6)
NT 8.1 (6.5–10.0) 0 70
43 NEG 6 NT 0 0 NT 0 0 NT 0 0 80
44 NEG 13 NT 0.9 (0.7–1.1) 0 NT 0 0 NT 0 0 80
48 NEG 2 NT 6.0 (4.8–7.4) 0 NT 5.1 (4.1–6.3) 0 NT 0 0 40
49 NEG 1 NT 1.8 (1.4–2.2) 0 NT 2.6 (2.1–3.2) 0 NT 0 0 40
51 NEG 1 NT 0 0 NT 0 0 NT 0 0 60
Binary ALK status by FISH analysis is indicated as positive (POS, ≥ 15% of positive nuclei) or negative (NEG, < 15% of 
positive nuclei). Percentage (%) of FISH positive nuclei with separated green and red signals or single red signals (translocation 
and deletion of the ALK 5′ portion, respectively) are reported when available. Binary ALK status determined by the PCR-based 
model analysis is indicated as Translocated (T) or Not Translocated (NT) based on the predicted percentage of 3′ and 5′ ALK 
positivity measured in each FFPE NSCLC sample using 100, 25 or 10 ng of RNA input (positivity cut-off values for the 3′ 
and 5′ ALK portions were 10% and 3%, respectively). Predicted percentages of 3′ and 5′ ALK positive RNA present in FFPE 
NSCLC samples are reported along with 95% confidence intervals in brackets. These values were calculated from the data 
obtained in the RT-qPCR analysis by the ALK inverse prediction models obtained from the Kelly calibration curves for the 3′ 
and 5′ portions of ALK. The model was derived considering the 1–50% dilution series of the external calibration curves. The 
percentage (%) of tumor cell content is also indicated for each sample. ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in situ hybridization; RT-qPCR, quantitative reverse transcription-polymerase chain reaction.
iii) it provides a quantitative assessment of 3′ and 5′ ALK 
mRNA positivity. Unlike traditional comparative (ΔΔCq) 
and/or 3′/5′ ratio methods derived thereof, our model 
provides confidence intervals for each point prediction. 
These interval estimates, by identifying the range of 
possible true values of the point prediction, will increase 
clinicians’ confidence about the prediction score and help 
guide them in therapy decision-making.
Novel multiplex NGS assays represent attractive 
diagnostic tools for the detection of clinically relevant 
genomic alterations associated with solid tumors including 
ALK translocations [36, 49]. An extended comparative 
analysis of our predictive model vs. emerging NGS 
assays, employing large NSCLC cohorts, and technically 
challenging FFPE specimens is warranted. However, our 
results clearly show that our PCR-based ALK test is highly 
accurate in surgical as well as cytological specimens. 
Therefore, our diagnostic assay not only can be employed 
as a confirmatory test of FISH and/or IHC results and to 
resolve equivocal FISH and/or IHC results, but can also be 
used as a first-line diagnostic tool for the rapid, efficacious 
and convenient screening of large patient populations.
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table 4: Accuracy of ALK status prediction in the 7 cytology specimens using 10 ng of input rnA
case
Id
FIsH rt-qPcr Model - Kelly (1–50%) - 10 ng rnA tumor cell
content (%)AlK
score
Positive
nuclei (%)
ALK
status
3′ ALK
Positivity (%)
5′ ALK
Positivity (%)
52 NEG 11 NT 0 0 60
53 NEG 9 NT 0 0 80
54 NEG 9 NT 0 0 30
55 NEG 12 NT 0 0 50
56 NEG 9 NT 0 14.6 (11.5–18.6) 40
57 POS 20 NT 0 0 70
58 POS 38 T 40.4 (32.5–50.4) 0 70
Binary ALK status by FISH analysis is indicated as positive (POS, ≥ 15% of positive nuclei) or negative (NEG, < 15% 
of positive nuclei). Percentage (%) of FISH positive nuclei with separated green and red signals or single red signals 
(translocation and deletion of the ALK 5′ portion, respectively) are reported. Binary ALK status determined by the PCR-based 
model analysis is indicated as Translocated (T) or Not Translocated (NT) based on the predicted percentage of 3′ and 5′ 
ALK positivity measured in each cytology sample using 10 ng of RNA input (positivity cut-off values for the 3′ and 5′ ALK 
portions were 10% and 3%, respectively). Predicted percentages of 3′ and 5′ ALK positive RNA present in FFPE NSCLC 
samples are reported along with 95% confidence intervals in brackets. These values were calculated from the data obtained 
in the RT-qPCR analysis by the ALK inverse prediction models obtained from the Kelly calibration curves for the 3′ and 5′ 
portions of ALK. The model was derived using the 1–50% dilution series of the external calibration curves. The percentage 
(%) of tumor cell content is also indicated for each sample. ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ 
hybridization; RT-qPCR, quantitative reverse transcription-polymerase chain reaction.
MAterIAls And MetHods
Human cell lines and samples
The human neuroblastoma cell line Kelly (DSMZ® 
ACC 355™) and the lung cancer cell line NCI-H2228 
(ATCC® CRL-5935™) were used as positive controls for 
the expression of full-length ALK transcript (ALKF1174L 
mutant) [2] and of translocated ALK (EML4-ALK) [5], 
respectively. The lung cancer cell line A549 (ATCC® CCL-
185™) was used as a negative control, since they express 
barely detectable levels of the normal ALK transcript 
[5]. Cells were cultured and used fresh or pelleted and 
processed into FFPE cell blocks for subsequent analyses. 
Cells were routinely tested for mycoplasma contamination 
[50] and multiplex short tandem repeat profiling test for 
authentication using the GenePrint® 10 System (Promega 
Corporation, Madison, WI, USA). 
All samples were derived from patients operated 
at the European Institute of Oncology (IEO), Milan, 
Italy. FFPE tissue blocks of ALK FISH-positive samples 
with sufficient biological material were available for 
17 patients. Based on the availability of these 17 FISH-
positive samples, we randomly selected 34 FISH-
negative controls, which together constituted a cohort 
of 51 NSCLC patients (with a 1:2 ratio of ALK positive 
vs. control samples). We also analyzed 7 cytological 
samples (cytoblocks), 5 FISH-negative and 2 FISH-
positive, with sufficient biological material obtained with 
the EBUS-TBNA procedure from patients with clinically 
diagnosed primary lung cancer. The clinico-pathological 
characteristics of the patients are described in Table 1. 
RNA was also extracted from FFPE non-pathological lung 
tissue samples, adjacent to diseased area, prepared from 
an additional 20 NSCLC patients. Each case was centrally 
reviewed to confirm the histopathological assessment and 
to verify the content of tumor or normal parenchyma. 
Investigations were conducted in accordance with the 
ethical standards as outlined in the Declaration of Helsinki 
and in national and international guidelines, and were 
approved by the IEO institutional review board.
Fluorescence in situ hybridization
ALK rearrangements were analyzed on 4 μm thick 
FFPE tissue sections, using the break-apart probe FISH 
Probe Kit (Vysis LSI ALK Dual Color, Abbott Molecular 
Inc.) according to manufacturer’s instructions. Samples 
were analyzed using an epifluorescence microscope 
(Leica, Wetzlar, Germany). Signal evaluation was 
performed in at least 60 nuclei as follows: i) separated 
green and red signals or single red signals (translocation 
and deletion of the ALK 5′ portion) in at least 15% of 
tumor cells analyzed; ii) overlapping of green and red 
signals (yellowish) indicated cells in which ALK was not 
rearranged.
Immunohistochemistry
ALK IHC was performed on 4 μm thick FFPE 
tissue sections using the fully automated Ventana IHC 
ALK (D5F3) CDx Assay (Ventana Medical Systems, 
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Inc., Tucson, AZ, USA), with the pre-diluted Ventana 
anti-ALK (D5F3) rabbit monoclonal primary antibody, 
the Optiview DAB IHC detection kit and Optiview 
Amplification kit on the Benchmark XT stainer. We 
adopted the binary scoring system (positive or negative 
for ALK status) to evaluate the staining results according 
to manufacturer’s recommendations. ALK positivity was 
assigned exclusively in the presence of a strong granular 
cytoplasmic staining in tumor cells (any percentage of 
positive tumor cells). 
rnA extraction and quantitative real-time Pcr 
Genetic material was isolated from fresh cell lines 
using the AllPrep DNA/RNA/miRNA Universal Kit 
(Qiagen, Hilden, Germany) and from FFPE cell blocks 
or tissue blocks using the AllPrep DNA/RNA FFPE Kit 
(Qiagen, Hilden, Germany). RNA was extracted from 
manually microdissected areas of 2 tissue sections (10 μm 
thick) on glass slides selected by a pathologist for each 
relevant FFPE tissue block. For standard mRNA analysis, 
500 ng of total RNA (RNA concentration measured using 
the NanoDrop® ND-1000 Spectrophotometer) were reverse 
transcribed with random primers using the SuperScript® 
VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific) 
and 5 ng or 20 ng of cDNA from fresh or FFPE cells, 
respectively, were then analyzed per reaction by PCR. In 
case of pre-amplification, 100, 25, and 10 ng (as indicated) 
of total RNA from FFPE cell blocks and/or FFPE tissue 
blocks were reverse transcribed, pre-amplified for 
10 cycles using the PreAMP Master Mix Kit (Thermo 
Fisher Scientific) according to manufacturer’s instructions, 
and diluted 1:5 prior to PCR analysis (5 µl were then used 
per PCR reaction, corresponding to 2, 0.5 or 0.2 ng of 
cDNA).
Quantitative PCR was performed with hydrolysis 
probes (Thermo Fisher Scientific) using the SsoAdvanced 
Universal Probes Supermix (Bio-Rad Laboratories) in 
10 μl of final volume in 384-well plates. PCR reaction was 
run in LightCycler (LC) 480 real-time PCR instruments 
(Roche) using the following thermal cycling conditions: 1 
cycle at 95°C for 30 sec, 45 cycles at 95°C for 5 sec, and 
60°C for 30 sec.
TaqMan gene expression assays, with short 
amplicon sizes, were as follows: Hs01058323_m1 
(human ALK, RefSeq NM_004304, exon boundary 
9–10, assay location 2775, amplicon length 66 bp), 
Hs00608292_m1 (human ALK, RefSeq NM_004304, 
exon boundary 27–28, assay location 5022, amplicon 
length 59 bp), Hs03929097_g1 (human GAPDH, RefSeq 
NM_001256799, exon boundary 8–8, assay location 
1250, amplicon length 58 bp), Hs99999908_m1 (human 
GUSB, RefSeq NM_000181, exon boundary 11–12, assay 
location 1925, amplicon length 81 bp) and Hs00427621_
m1 (human TBP, RefSeq NM_001172085, exon boundary 
3–4, assay location 666, amplicon length 65 bp) (sequence 
details in Supplementary Table S9). 
We defined Cq = 40 as our limit of detection in the 
absence of pre-amplification and Cq = 30 in the presence 
of the pre-amplification, based on the lowest Cq value 
measured for the two ALK assays in the negative control 
cell line A549 (Supplementary Table S1). Cq values 
beyond these limits were set to 40 or 30, accordingly, 
and normalization was omitted. Each target was assayed 
in triplicate and average Cq values were calculated either 
from triplicate values when the standard deviation was 
< 0.4, or from the best duplicate values when the standard 
deviation was ≥ 0.4. In each sample, the average Cq value 
of the 3′ or 5′ portion of ALK (CqALK) was normalized on 
the average Cq (Cq
REF
) value of three human reference 
genes (GAPDH, GUSB and TBP), to account for variation 
in the expression of single reference genes and in RNA 
integrity due to tissue fixation, using the following 
formula:
ΔCq = CqALK – mean CqREF 
Pre-amplification uniformity for each ALK 
gene expression assay was measured in Kelly cells by 
calculating the ΔCq for each of the two ALK assays 
(ΔCq = Cq
3′/5′ALK
 – mean Cq
REF
) and by determining the 
ΔΔCq between pre-amplified (PreAmp) and not-pre-
amplified cDNA templates (ΔΔCq = ΔCq
PreAmp
 – ΔCq
cDNA
). 
Minus-reverse transcriptase (“−RT”) controls were also 
performed for pre-amplified cDNA templates to confirm 
the specificity of the ALK assays. “−RT” controls were 
negative both for the 3′ and 5′ ALK assays (all samples 
were flagged as “undetectable”). Based on the distribution 
of the reference genes, we applied the Tukey’s interquartile 
rule for outliers [51] to identify poor quality RT-qPCR 
data in the cohort of 51 FFPE NSCLC samples. 
development of the predictive model  
for the assessment of ALK status in tumor  
specimens
We prepared two different calibration curves 
using an artificial dilution series of total RNA derived 
from FFPE blocks of either Kelly cells expressing full-
length ALK or NCI-H2228 cells expressing EML4-ALK, 
mixed with total RNA from ALK negative A549 cells. 
Each curve was composed of 23 data points, obtained by 
diluting RNA from positive cells with increasing amounts 
of RNA from negative cells until a mixture composed 
of 1% NCI-H2228/Kelly RNA and 99% A549 RNA 
was reached. The upper half of the curve (50–100% of 
RNA from positive cells) was obtained using discrete 
increments of 10% of RNA from negative cells. To 
improve the resolution of the ALK assay in the lower half 
of the calibration curve (0–50%), RNA from positive cells 
was diluted using progressively smaller increments of 
RNA from negative cells as follows: 5% increments in the 
25–50% range, 2.5% increments in the 5–25% range, and 
1% increments in the 1–5% range. We reverse transcribed 
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500 ng or 100 ng of total RNA for each data point of the 
calibration curve in the absence or in the presence of pre-
amplification, respectively, prior to PCR analysis.
The level of expression of the 3′ and/or the 5′ portion 
of the ALK transcript measured by PCR was regressed 
on the known percentage (log-transformed, base 10) 
of total ALK-positive RNA present in each data point of 
the calibration curve analyzed. The inverse prediction 
approach was applied to predict the actual percentage 
of 3′ and/or 5′ ALK-positive transcript, as well as 95% 
confidence intervals from the values obtained in the RT-
qPCR analysis [44]. 
We employed both Kelly and NCI-H2228 
calibration curves, separately or pooled, to build 
the predictive models for the 3′ portion; the Kelly 
calibration curve alone was used for the 5′ portion of 
ALK. To improve the performance of the assay when 
ALK is expressed at low/moderate levels in unknown 
NSCLC samples, we also generated predictive models 
by including only the data points in the 1–50% dilution 
range. Coefficient of determination (R2) and residual 
sum of squares (RSS) values were calculated to assess 
the goodness of the various fits. To evaluate the basal 
level of expression of both the 5′ and 3′ portions of ALK, 
we applied the different predictive models to the set of 
20 lung FFPE non-pathological tissue samples. The 
threshold value of ALK positivity (abnormal ALK 
expression) was established based on the median of the 
95th percentiles of the predictions obtained from each 
of the different models. Finally, these inverse predictive 
models were validated in the cohort of 51 FFPE human 
samples. Translocation was assigned based on unbalanced 
interval estimates of 3′ and 5′ ALK predictions. Statistical 
analyses were performed using SAS (SAS 9.3, SAS 
Institute, Cary, NC, USA).
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